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differences between G2 and G3 stage breast cancers,
and correlations of PKCrj with MDRI, MRP and LRP
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Summary A possible link between protein kinase C (PKC) and P-glycoprotein (P-gp)-mediated-multidrug resistance (MDR) was assumed
from studies on MDR cell lines selected in vitro. The functional relevance of PKC for the MDR phenotype remains unclear, and the
involvement of a particular PKC isozyme in clinically occurring drug resistance is not known. Recently, we have demonstrated significant
correlations between the expression levels of the PKC'q isozyme and the MDR1 or MRP (multidrug resistance-associated protein) genes in
blasts from patients with acute myelogenous leukaemia (AML) and in ascites cell aspirates from ovarian cancer patients. To extend these
findings to further types of human tumours we analysed specimens from 64 patients with primary breast cancerfortheir individual expression
levels of several MDR-associated genes (MDR1, MRP, LRP (lung cancer resistance-related protein), topoisomerase (Topo) Ila/lip, cyclin A
and the PKCisozyme genes (a, P,, P21 ii, 0 and j) by a cDNA-PCR approach. We found significantly enhanced mean values for MRP, LRP
and PKCn gene expression, but significantly decreased Topo Ila and cyclin A gene expression levels in G2 tumours compared with G3.
Remarkably, significant positive correlations between the MDR1, MRP or LRP gene expression levels and PKCr were determined:
MDR1/PKC0 (rs = +0.6451, P< 0.0001) n = 62; MRPIPKCri (r, = +0.5454, P < 0.0001) n = 63; LRPIPKGYj (r, = +0.5436, P< 0.0001) n = 62;
MRPILRP(rr = +0.7703, P < 0.0001) and n = 62, MDR1/MRP (rs = +0.5042, P< 0.0001) n = 62. Our findings point to the occurrence of a
multifactorial MDR in the clinics and to PKCn as a possible key regulatory factor for up-regulation of a series of MDR-associated genes in
different types of tumours.
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The successful treatment of breast cancer using antineoplastic
agents is often limited by the occurrence of drug resistance.
Studies on cell lines selected in vitro revealed different mecha-
nisms eventually responsible forthe observed multidrug resistance
(MDR), such as the overexpression of (a) the P-glycoprotein
(P-gp) drug transporter (for review see Germann, 1996), (b) the
'multidrug resistance-associated protein' (MRP) that represents
another ATP-binding cassette membrane glycoprotein also trans-
porting drug conjugates (for review see Loe et al, 1996), (c) the
'lung cancer resistance-related protein' (LRP) that was described
first in a MDR cell line lacking enhanced P-gp expression, charac-
terized as a human major vaultprotein (forreview see Izquierdo et
al, 1996) and (4) a decreased activity oftopoisomerase II (Topo II)
(for review see Nitiss and Beck, 1996).
An influence of protein kinase C (PKC) on P-gp-mediated
MDR is suggested as well, but it still remains unclear how PKC or
particular PKC isozymes might be functionally involved here: (a)
in vitro studies on cell lines gave evidence that P-gp is directly
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phosphorylated by PKC (Chambers et al, 1990a,b); (b) co-overex-
pression of PKCa pointed to a possible role of this PKC isozyme
in MDR of breast cancer cell lines (Yu et al, 1991); (c) MRP-
mediated MDR was significantly modulated by the specific PKC
inhibitor GO 6850 (Gekeler et al, 1995); but (d) PKC-mediated
phosphorylation of P-gp seems not to be significantly associated
with altered P-gp drug transport function (Scala et al, 1995;
Gekeler et al, 1996; Germann et al, 1996). Remarkably, the induc-
tion of a P-gp-mediated MDR in cell lines using different anti-
cancer drugs (Gekeler et al, 1988; 1994; Sato et al, 1990) could be
attenuated by using protein kinase inhibitors such as stauro-
sporine, which suggested a protein kinase-triggered stress
response ofcells including the up-regulation at least ofthe human
MDR1 gene (Chaudhary and Roninson, 1993; Blobe et al, 1994;
Grunicke et al, 1994).
We recently reported enhanced MDR1 and MRP gene expres-
sion levels in blasts ofrelapsed state AML patients, together with
a significant general correlation of PKCTI with MDR1 or MRP
gene expression, and, additionally, a significant correlation
between PKCO and MRP gene expression levels (Beck et al,
1996a). We also found elevated expression of the MDR1, MRP
and LRP genes together with elevated PKCl mRNA levels in
ascites cell aspirates obtained from ovarian cancer patients after
chemotherapy (Beck et al, 1996b). Based on these findings, we
hypothesized that PKCTl could represent a key regulatory factor
8788 J Beck et al
for up-regulation of various MDR-associated genes in response to
chemotherapy. To further substantiate these observations, we




We investigated solid tumour specimens from 64 women with
primary breast cancer within a prospective study from January
1994 to December 1995. The median age was 58 years ranging
from 37 to 88 years. A total of 35 patients showed positive node
status, whereas 29 were staged as negative. Metastases were
initially detectable in three patients. None ofthe patients received
radiotherapy or chemotherapy before the collection of samples.
Pathological examination showed 54 invasive ductal carcinomas,
two invasive medullary carcinomas, one invasive lobular carci-
noma, one carcinoma of the mucous type and six cases showed
features of two different types of carcinomas simultaneously. A
total of 32 tumours were classified GI, GI-2 or G2 and 32 were
assigned G2-3 or G3. Histological grading (Gl =high, G2 = inter-
mediate and G3 = low grade) was performed according to Bloom
and Richardson (1957).
Cell lines
The parental human breast cancer cell line MCF7 was obtained
from the American Type Culture Collection, Rockville, MD, USA
(ATCC HTB-22). It was originally derived from tumour cells from
a breast cancer patient with pleural effusion. MCF7/ADR is a
corresponding doxorubicin-selected P-gp overexpressing cell line
(Batist et al, 1986).
Tumour samples and RNA isolation
We obtained fresh tumourtissues from breast cancerpatients when
tumours were extracted during surgery. The identity of tumour
tissue was evaluated with the help of a pathologist. We stored
samples immediately at -80°C. RNA was isolated within 2 weeks
or the probes were transferred to liquid nitrogen. To isolate whole
cellular RNA, tissues were cut into small pieces immediately after
thawing and were subsequently homogenized in a Potter homo-
genizer in the presence of 4M guanidinium isothiocyanate
prewarmed to 65°C. The solution was then loaded onto a 5.7 M
solution of caesium chloride and RNA was isolated after ultra-
centrifugation according to Chirgwin et al (1979).
cDNA-PCR
Conditions for cDNA synthesis and semiquantitative polymerase
chain reaction (PCR) were performed, as reported previously (Beck
et al, 1995). Briefly, cDNA was synthesized by incubation with
RAV2 reverse transcriptase (9 U jig-') and PCR was performed
using Taq DNA polymerase (2.5 U 200 ng-' cDNA equivalent)
(both enzymes were obtained from Amersham, Braunschweig,
Germany). To minimize cross-contamination, samples taken for
cDNA synthesis or PCR were carefully prepared using separate
solutions, pipettes and centrifuges. To rule out false positives even-
tually generated from genomic DNA or cross-contamination ofthe
PCR amplified material, samples lacking reverse transcriptase were
examined at fixed-time intervals. PCR products were separated by
polyacrylamide gel electrophoresis and then stained with ethidium
bromide. Signals were directly digitalized using the CS1 video-
imager (Cybertech, Berlin, Germany) and densitometrically
analysed using WINCAM software (Cybertech). The specific
signals were normalized to the signals obtained using the
amplimers for the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene (internal standard). This value was then referred to
the corresponding value seen with material of the MDR breast
cancer cell line MCF7/ADR. The expression levels of all genes
included in our analysis in the material of this cell line were arbi-
trarily set to 100%. Experiments were carried out at least twice.
Mean values were taken for further analysis. Reproducibility of
experiments was generally found to be within the range of 10-20%.
Primer pairs
Primer pairs and conditions for PCR of GAPDH, MDR1, MRP,
Topo 11a, Topo II and cyclinA (Beck et al, 1995), PKC (a, P, 2,
ig, 0) (Beck et al, 1996a), LRP and PKCj (Beck et al, 1996b) were
adopted from previous studies.
Table 1 Mean values obtained by semiquantitative cDNA-PCR of relative MDR1, MRP, LRP, PKC (a, 1, 0, g), Topo llax/111 and cyclin A gene expression levels
± standard deviations in G2, G2-3 and G3 classified primary breast cancers and, in comparison, in the parental breast cancer cell line MCF7
MCF7 G2 (n) G2-3 (n) G3 (n) P-value (G2 vs G3)
MDR1 Not detectable 60 ± 44 (29) 25 ± 21 (18) 34 + 33 (13) Not significant
MRP 65 218 ± 125 (30) 174 ± 81 (18) 155 ± 87 (13) P< 0.05
LRP 34 1003 ± 713 (30) 762 ± 299 (17) 629 ± 545 (13) P< 0.05
PKCa 20 88 ± 25 (29) 73 ± 21 (19) 84 ± 34 (13) Not significant
PKCrl 220 720 ± 385 (30) 496 ± 235 (18) 502 ± 444 (13) P< 0.05
PKCO 12 63 ± 45 (30) 72 ± 67 (19) 63 ± 35 (13) Not significant
PKC1I 30 108 ± 77 (30) 99 ± 70 (17) 80 ± 56 (13) Not significant
cyclin A 117 50 ± 17 (30) 78 ± 48 (19) 88± 32 (13) P< 0.0005
Topolla 160 95 ± 34 (30) 119 ± 30 (19) 130+ 41 (13) P< 0.01
Topo ll3 156 141 ± 36 (30) 157 ± 41 (19) 135 ± 39 (13) Not significant
The individual signals have been normalized to the signals corresponding to the internal standard gene GAPDH. These values were then referred to the
corresponding values found in the material of the MDR cell line MCF7/ADR (reference value arbitrarily set to 100% for the expression level of each gene
investigated). The P-value indicates significant differences between the levels of gene expression in G2 and G3 classified tumours
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Figure 1 Separation of PCR products (GAPDH, MDR1, MRP, LRP, Topo
Ila, TopoIl, and PKCrI) as indicated using polyacrylamide gel
electrophoresis. MCF7 is the parental breast cancer cell line, MCF7/ADR is
the corresponding doxorubicin selected multidrug-resistant cell line
overexpressing the MDR1 gene that served as the standard for the genes
investigated. A and B represent patients with G2 staged breast cancers,
C and D were assigned to G3
Immunohistochemistry
The P-gp content at the protein level was determined on cryostat
sections from several tumour samples by immunohistochemistry
(Cordell et al, 1984) using the MRK16 anti-P-gp monoclonal anti-
body (Syrinx, Frankfurt, Germany) together with reagents from a
detection kit (Dako, Hamburg, Germany). According to the extent
of P-gp expression levels found, the samples were categorized
from 0 (weak) to 5 (strong).
Statistics
Statistical analysis was performed for different purposes: (a) we
asked whether an altered expression of resistance-associated genes
in G2 and G3 breast cancers might correspond with the differences
of a clinically observed drug resistance. We therefore performed
the Mann-Whitney U-test to calculate the significance of differ-
ences between the various cohorts concerning their gene expres-
sion levels. (b) In previous studies we observed correlations
between the expression levels of resistance-associated genes and
PKCrl in AML and in ascites aspirates from ovarian cancer
patients. A similar observation was reported for Topo IlIa and
cyclin A expression levels (Beck et al, 1995; 1996a). In the present
study, we asked whether such correlations might also exist in spec-
imens obtained from breast cancer patients. We used Spearman's
rank order correlation test for these variables. To test for correla-
tions that might include other parameters we used this test for
other values determined within this study. However, statistical
significance might be affected when multiple parameters are
compared by increasing the probability of finding correlations just
by chance. Therefore, our results from the statistical analysis
should be taken as a first explorative description. Results are
presented when the P-value was < 0.05 and rs exceeded > 0.500.
RESULTS
We determined the individual relative expression levels of the
resistance-associated genes (MDRl, MRP, LRP, Topo IIa/II) and
the PKC isozyme (a, Pi , r2, e, g) genes in 64 breast cancer
specimens using a cDNA-PCR approach. In addition, we
measured cyclin A gene expression levels as a marker for cellular
proliferative activity (Pines and Hunter, 1990).
The expression analysis revealed significantly higher mean
values for cyclin A and Topo Ila together with lower values for
MRP, LRP and PKCrI in G3 tumours than in G2 tumours (Table 1).
Moreover, we found significant positive correlations for
MDRl/PKCrl (rs= +0.6451, P<0.0001), n = 62; MRPIPKCrT
(rs = +0.5454, P<0.0001), n = 63; LRPIPKCri (rs = +0.5436,
P < 0.0001) n = 62; MRPILRP (rs = +0.7703, P < 0.0001) n = 62;
MDRIIMRP (r, = +0.5042, P < 0.0001) n = 62 and also between
cyclin A and Topo Ilcc gene expression (rs = +0.6408, P < 0.0001)
n = 64. Nothing alike was observed in the case of the PKCcx, PKCO
or PKCp isozyme mRNA expression levels. Any correlations with
staging of the patients according to the TNM (T, tumour size; N,
lymph nodes infiltrated by tumour cells; and M, metastasis) classi-
fication were not observed.
Our estimation of P-gp at the protein level determined by
immunohistochemistry (data not shown) correlated significantly
with the MDR1 gene expression analysis using cDNA-PCR
(rs = +0.7848, P < 0.001, n = 14).
These results were obtained from statistical analysis that tested
multiple parameters against each other. However, in breast
cancers, the test showed highest correlations exactly for those vari-
ables we also found in previous studies in other tumour tissues.
Therefore, we suggest that the results might be of importance
and should provide a basis for further investigations at the
functional level.
Remarkably, expression of the PKCP, and , genes was not
detectable either in the primary breast cancer specimens or in
material of the MCF7 cell lines by our cDNA-PCR approach
applying 32 (PKC,1) or 28 (PKCP2) cycles respectively.
Therefore, these genes are not listed in the table. Nonetheless, this
observation might be important as distinct PKCP, and P2 gene
expression was found in normal lymphocytes under the same
conditions (J Beck et al, unpublished results). In fact, in a series of
dilution experiments with total RNA prepared from the MCF7 cell
line or normal peripheral blood mononuclear cells (PBMCs) we
found distinct PKCf expression signals if the fraction of added
PBMC RNA amounts only to 5%. Thus, a lack of signals corre-
sponding to PKCf might indicate that the tumour samples did
not contain significant amounts of PBMCs that may give false
positives concerning MDR1 gene expression.
DISCUSSION
Standard breast cancer chemotherapeutic regimens include doxoru-
bicin, taxol and vinblastine. Each of these compounds is included in
the resistance profile of either MDRI or MRP overexpressing cells.
The functional involvement of LRP in a cellular resistance towards
these drugs remains to be clarified, however. The activity of topo-
isomerases supposedly affects the sensitivity towards topoisomerase
inhibitors such as doxorubicin, but cellular proliferation activity
could influence the effects of antiproliferative drugs in general.
Retrospective clinical studies showed that breast cancer tissues with
high proliferation indices and a low grade ofdifferentiation generally
respond better to chemotherapy (Silvestrini and Daidone, 1993). Our
present analysis demonstrates that Topo IIcl and cyclin A gene
expression levels are significantly lower in G2 than in G3 classified
tumours. This corresponds well to the enhanced proliferation activity
and lower differentiation grade ofG3 tumours than G2 tumours, and
the better response ofG3 tumours to chemotherapy.
Furthermore, the MRP and LRP gene expression levels were
significantly higher in G2 tumours than in G3 classified tumours.
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This agrees with a previous study on bladder carcinomas that
revealed enhanced MRP gene expression levels in the higher
differentiated GI and G2 tumours compared with G3 tumours
(Clifford et al, 1996). Thus, our results might explain the better
responsiveness of G3 staged breast cancers to chemotherapeutic
regimens, which may depend not only on the enhanced prolifera-
tion rate together with higher activity of Topo IIa but also on the
lower expression levels ofthe MRP and LRP genes compared with
G2 staged tumours. In contrast, the drug resistance generally seen
in more differentiated primary breast cancers with lower prolifera-
tive activity appears to be mediated by multiple factors. However,
it is too early to take the observed variations in gene expression
levels between the G2/G3 cohorts as prognostic factors for the
outcome of treatment in the case ofpatients included in our study
because the observation period after the date ofprimary diagnosis
is still too short.
Recently, we demonstrated in AML blasts a significant positive
correlation between the PKCTI and MDR1 or MRP gene expres-
sion levels, respectively, and in addition between PKCO and MRP
levels (Beck et al, 1996a). Furthermore, we found enhanced PKCn
mRNA expression together with higher expression of MDRI,
MRP and LRP in ascites cell aspirates from ovarian cancer patients
(Beck et al, 1996b). Our analysis on breast cancer samples gives
very similar results to these earlier studies, i.e. a significant corre-
lation ofrelative PKCrI and MDR1, MRP or LRP gene expression
levels, respectively. Therefore, we suggest that this particular PKC
isozyme might be directly involved in either the expression status
of MDR associated genes or the differentiation stage of primary
breast cancer tumour cells. This hypothesis might be supported by
recent findings that PKCTl is predominantly located in the cell
nucleus of skin-derived human cells. Accordingly, a possible
direct regulatory function ofPKCl at the transcriptional level was
suggested (Greif et al, 1994).
However, other investigators have already analysed MDRl/P-gp
expression in breast cancers using different methods. Although these
results showed a great variability, the majority ofinvestigators found
relatively high MDRl/P-gp expression in tumours treated with drugs
involved in P-gp-mediated MDR (Goldstein etal, 1989; Schneideret
al, 1989; Ro et al, 1990; Sanfilippo et al, 1991). Therefore, it seems
interesting to determine whether and to whatextentapossible induc-
tion of resistance-associated genes in response to chemotherapeutic
regimens might be controlled by PKCrl.
ABBREVIATIONS
LRP, lung cancer resistance related protein; MDR, multidrug
resistance; MRP, multidrug resistance-associated protein; P-gp,
P-glycoprotein; PKC, protein kinase C, Topo II, topoisomerase II.
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